GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM39430
Query DataSets for GSM39430
Status
Public on Apr 01, 2005
Title
pp122-3
Sample type
RNA
Source name
Staged C. elegans embryos
Organism
Caenorhabditis elegans
Extracted molecule
total RNA
Description
Mutant genotype pie-1(zu154); pal-1(RNAi) 122 minutes after the 4-cell embryonic stage at 22 degrees C
Sample_genotype: pp
Sample_time: 122
Submission date
Jan 24, 2005
Last update date
May 27, 2005
Contact name
Andrew Hill
E-mail(s)
andrew.hill@pfizer.com
Phone
617-674-6341
Organization name
Pfizer
Department
Research Business Technology
Street address
300 Technology Square
City
Cambridge
State/province
MA
ZIP/Postal code
02139
Country
USA
Platform ID
GPL200
Series (1)
GSE2180
C. elegans embryonic timecourse in wt and mutant embryos
Data table header descriptions
ID_REF
Affymetrix Qualifier
VALUE
RMA calulated using Bioconductor Affy package (http://www.bioconductor.org)
Data table
ID_REF
VALUE
171720_x_at
3.71315371084096
171721_x_at
5.8892051850814
171722_x_at
6.43491977592125
171723_x_at
3.26326942907657
171724_x_at
3.73517278200643
171725_x_at
3.96123801730368
171726_x_at
4.80743114458851
171727_x_at
2.84517774232323
171728_x_at
2.99375018253651
171729_x_at
7.16630962533378
171730_x_at
2.98423243387908
171731_x_at
8.31249806653442
171732_x_at
6.78139463073503
171733_x_at
9.8901330350472
171734_x_at
9.71148677669636
171735_x_at
3.03643903839833
171736_x_at
7.86535692079138
171737_x_at
7.96463682542147
171738_x_at
6.21936959401751
171739_x_at
3.02698933725748
Total number of rows:
22625
Table truncated, full table size
608 Kbytes
.
Supplementary file
Size
Download
File type/resource
GSM39430.CEL.gz
2.6 Mb
(ftp)
(http)
CEL
GSM39430.EXP.gz
327 b
(ftp)
(http)
EXP
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|
